Abstract
Symptomatic vs. Disease-modifying treatments in neurological diseases: Where next? An optimal drug for chronic neurological disease would slow down disease progression in the long term, with short-term symptomatic benefits. This would shorten clinical development timelines and reduce the cost and risk level for drug developers. Henri Huttunen Chief Scientific Officer (CSO) at Herantis Pharma Plc explains. In Parkinson’s disease (PD), the development of motor symptoms is associated with the degeneration of dopamine-producing nerve cells in the midbrain. For decades, motor symptoms of PD have been treated with levodopa, a precursor of dopamine, which helps to replenish dopamine levels in brain areas coordinating movement. Levodopa is an example of a symptomatic treatment as it improves symptoms but does not interfere with the underlying causes or progression of the disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
